Haleon plc (NYSE:HLN) Shares Bought by Royal Bank of Canada

Royal Bank of Canada boosted its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 62.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,733,615 shares of the company's stock after buying an additional 1,052,462 shares during the quarter. Royal Bank of Canada owned 0.06% of Haleon worth $26,078,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new position in Haleon during the fourth quarter worth about $45,110,000. Quantinno Capital Management LP grew its position in Haleon by 17.9% during the fourth quarter. Quantinno Capital Management LP now owns 577,518 shares of the company's stock worth $5,510,000 after buying an additional 87,557 shares during the period. OMERS ADMINISTRATION Corp grew its position in Haleon by 454.9% during the fourth quarter. OMERS ADMINISTRATION Corp now owns 102,100 shares of the company's stock worth $974,000 after buying an additional 83,700 shares during the period. Marathon Partners Equity Management LLC acquired a new position in Haleon during the fourth quarter worth about $1,192,000. Finally, Millennium Management LLC grew its position in Haleon by 82.5% during the fourth quarter. Millennium Management LLC now owns 528,891 shares of the company's stock worth $5,046,000 after buying an additional 239,019 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Trading Up 0.3%

Shares of HLN traded up $0.04 on Thursday, hitting $11.29. 6,770,430 shares of the stock traded hands, compared to its average volume of 8,340,173. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $50.86 billion, a P/E ratio of 33.25, a P/E/G ratio of 2.82 and a beta of 0.24. The stock's 50 day moving average is $10.35 and its two-hundred day moving average is $9.94. Haleon plc has a 1 year low of $8.25 and a 1 year high of $11.36.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, sell-side analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

HLN has been the topic of several research reports. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.